GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...

GSK announced a major breakthrough concerning cancer therapy. A drug called Jemperli (dostarlimab) showed impressive results in a phase 2 trial at the Memorial Sloan Kettering Cancer Center (MSK).

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

The safety and efficacy of dostarlimab plus chemotherapy in patients with advanced endometrial cancer were confirmed by ...

The drug, called dostarlimab and sold under the brand name Jemperli, is an immunotherapy drug used to treat endometrial cancer, but this was the first clinical trial to see if it was equally ...